- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03810599
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study (BECARES)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Tone M Norekvål, PhD
- Phone Number: +4799044635
- Email: tone.merete.norekval@helse-bergen.no
Study Contact Backup
- Name: Nina B Fålun, MSc
- Phone Number: +4790858527
- Email: nina.falun@helse-bergen.no
Study Locations
-
-
-
Bergen, Norway, 5021
- Recruiting
- Haukeland University Hospital
-
Contact:
- Tone M Norekvål, PhD
- Phone Number: +4799044635
- Email: tone.merete.norekval@helse-bergen.no
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of coronary artery disease
- >=18 years of age
- Has performed a negative exercise test (bike or treadmill) and thereby able to participate in exercise training.
Exclusion Criteria:
- Cognitive impairment
- Unstable angina pectoris
- Aortic stenosis
- Left ventricular ejection fraction <30%
- Heart failure NYHA class III-IV
- Serious arrhythmia in need of treatment
- Being on the waiting list for percutaneous coronary intervention or coronary artery bypass grafting.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Early cardiac rehabilitation
Single Group: 5 week cardiac rehabilitation programme.
Pre-post comparison.
|
This is an early cardiac rehabilitation programme starting 1-2 weeks after hospital discharge (Phase 2A rehabilitation). The programme provided by a multidisciplinary team includes individual counseling, educational sessions and discussion in groups, and exercise training sessions three days a week for five weeks. For additional analysis there will be a comparison group that did not receive the intervention for practical reasons. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to composite of total mortality, and hospitalization for heart failure and atherothrombotic disease (including non-fatal MI, unstable angina and stroke).
Time Frame: Up to 10 years
|
Time to combined endpoint from inclusion.
|
Up to 10 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Self-reported health
Time Frame: Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
|
The EuroQol 5-dimensions-5 level questionnaire (EQ-5D-5L) is an 5 item self-report-questionnaire assessing self-reported health.
The respondent rates each item on a 5-point scale ranging from 1(indicating no problem) to 5 (indicating extreme problems).
This decision results in a 1-digit number that expresses the level selected for that dimension.
The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
|
Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
|
Change in self-reported global health
Time Frame: Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
|
The VAS scale from the EQ-5D-5L assess global health.
The scale goes from 0 to 100 were lower score indicates worse health.
|
Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
|
Change in post traumatic growth
Time Frame: Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
|
The Posttraumatic Growth Inventory-Short Form (PTGI-SF) is a 10 item scale measuring post traumatic growth.
The respondent rates each item on a 6-point scale ranging from 0 (I did not experience this change as a result of my crisis) to 5 (I experienced this change to a very great degree as a result of my crisis).
The scale is scored by adding all the responses.Individual factors are scored by adding responses to items on each factor.
Factors are indicated by the Roman numerals after each item.
|
Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
|
Nicotine dependence
Time Frame: Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
|
The Fagerström test
|
Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
|
Change in anxiety and depression
Time Frame: Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
|
The Hospital Anxiety and Depression Scale (HADS) is a fourteen item scale where seven of the items relate to anxiety and seven relate to depression.
The respondent rates each item on a 4-point scale ranging from 0 (absence) to 3 (extreme presence).
The total score is 42 (21 per subscale).
|
Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
|
Change in physical and mental dimensions of health
Time Frame: Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
|
The Short Form Health Survey (SF-12) include 12 items with 3 to 5 response levels.
It generates two health indices: mental health and physical health.
The score range between 0 and 100, with 100 representing the highest level of health
|
Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
|
Change in health status following myocardial infarction
Time Frame: Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
|
The Myocardial Infarction Dimensional Assessment Scale (MIDAS) is a PRO measure developed and validated to specifically measure the health status of individuals who have suffered a myocardial infarction.
It consist of 7 domains, and is a 35 item scale where respondents rate each item on a 5-point scale ranging from 1 (never) to 5 (always).
The function of the MIDAS is to indicate the extent of ill health in each of the seven domains assessed, therefore each dimension is scored separately using a simple scoring methodology.
|
Immediately after the 5 week intervention, and at 9, 31, 57 and 109 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Tone M Norekvål, PhD, Haukeland University Hospital
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014/333
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Early cardiac rehabilitation
-
Ospedale Generale Di Zona Moriggia-PelasciniUnknownBrain Injury | Tracheostomy | Neurological RehabilitationItaly
-
Wake Forest University Health SciencesRecruitingCardiac AmyloidosisUnited States
-
Lawson Health Research InstituteHeart and Stroke Foundation of OntarioCompleted
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Heart DiseaseUnited States
-
Lawson Health Research InstituteCanadian Institutes of Health Research (CIHR); AstraZenecaCompletedMyocardial Infarction | Coronary Disease | Unstable AnginaCanada
-
University of California, San FranciscoPatient-Centered Outcomes Research Institute; Johns Hopkins University; Mayo... and other collaboratorsRecruitingMyocardial Infarction | Coronary Artery Disease | Heart Valve Diseases | Angina, Stable | Heart Failure, Systolic | Heart TransplantUnited States
-
Federico II UniversityCompletedAcute Myocardial InfarctionItaly
-
Cairo UniversityNational Heart Institute, EgyptCompletedChronic Heart FailureEgypt
-
Women's College HospitalRecruiting
-
Parc de Salut MarAsociación Española contra el CáncerCompletedCancer of Head and NeckSpain